Last June, I testified before a Reference Committee at the annual meeting of the American Medical Association, explaining a resolution that American Society of Addiction Medicine had brought forward to encourage the Food and Drug Administration to reschedule hydrocodone combination products from Schedule III to Schedule II. I expected there to be few others testifying. I wasn’t at all ready for the long line of individuals standing at the “con” microphone, ready to speak against the resolution, says Dr. Stuart Gitlow, ASAM President.
As a growing number of states have either passed new legislation or are considering legislation limiting payment for opioid treatment, the American Society of Addiction Medicine has launched a task force focused on FDA-approved medications for opioid dependence, says their Acting President Dr. Stuart Gitlow.
With Election Day just around the corner, voters in multiple locations will again be confronted with cannabis-related questions. Stuart Gitlow, MD, MPH, Acting President of the American Society of Addiction Medicine, says “medical marijuana” has simply been the camel’s nose under the tent, with the true goal of legalization covered up with a supposedly scientific approach.
The demand for addiction treatment is high. The supply of addiction specialists is comparatively low. Yet unlike traditional economic models where money is the obstacle, in our field, the obstacle is time explains Dr. Stuart Gitlow, member of the AMA’s Council on Science & Public Health, and Acting President of the ASAM.
Addiction is a complex lifelong disease which, if unaddressed, commonly results in death of the patient. Dr. Stuart Gitlow of the American Society of Addiction Medicine asks, shouldn’t we have some research to determine to whom these patients should be referred?